Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim F Greten

Showing results (91-100 of 223) with videos related to

Pageof 23
Sort By:
Journal for Immunotherapy of Cancer|November 22, 2017
Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancerZachary J Brown, Bernd Heinrich, Seth M Steinberg, et al.
Journal of Leukocyte Biology|October 19, 2012
Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing miceChi Ma, Tamar Kapanadze, Jaba Gamrekelashvili, et al.
Radiology|November 19, 2024
Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular CarcinomaRyan Bitar, Riad Salem, Richard Finn, et al.
Radiology|February 25, 2025
Erratum for: Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular CarcinomaRyan Bitar, Riad Salem, Richard Finn, et al.
Trends in Cancer|March 25, 2022
The gut-liver axis: host microbiota interactions shape hepatocarcinogenesisMaruhen A D Silveira, Steve Bilodeau, Tim F Greten, et al.
Journal of Hepatology|December 3, 2020
Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysisSophia Heinrich, Amanda J Craig, Lichun Ma, et al.
Carcinogenesis|July 10, 2023
The current landscape of therapies for hepatocellular carcinomaKelley Coffman-D'Annibale, Changqing Xie, Donna M Hrones, et al.
Plos One|November 18, 2014
Tumor induced hepatic myeloid derived suppressor cells can cause moderate liver damageTobias Eggert, José Medina-Echeverz, Tamar Kapanadze, et al.
Cancer Research|March 23, 2005
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinomaLars A Ormandy, Tina Hillemann, Heiner Wedemeyer, et al.
Gut|May 28, 2013
Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10Tobias Eggert, Katherine A McGlynn, Austin Duffy, et al.
Pageof 23

Showing results (91-100 of 223) with videos related to

Sort By:
Pageof 23
Journal for Immunotherapy of Cancer|November 22, 2017
Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancerZachary J Brown, Bernd Heinrich, Seth M Steinberg, et al.
Journal of Leukocyte Biology|October 19, 2012
Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing miceChi Ma, Tamar Kapanadze, Jaba Gamrekelashvili, et al.
Radiology|November 19, 2024
Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular CarcinomaRyan Bitar, Riad Salem, Richard Finn, et al.
Radiology|February 25, 2025
Erratum for: Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular CarcinomaRyan Bitar, Riad Salem, Richard Finn, et al.
Trends in Cancer|March 25, 2022
The gut-liver axis: host microbiota interactions shape hepatocarcinogenesisMaruhen A D Silveira, Steve Bilodeau, Tim F Greten, et al.
Journal of Hepatology|December 3, 2020
Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysisSophia Heinrich, Amanda J Craig, Lichun Ma, et al.
Carcinogenesis|July 10, 2023
The current landscape of therapies for hepatocellular carcinomaKelley Coffman-D'Annibale, Changqing Xie, Donna M Hrones, et al.
Plos One|November 18, 2014
Tumor induced hepatic myeloid derived suppressor cells can cause moderate liver damageTobias Eggert, José Medina-Echeverz, Tamar Kapanadze, et al.
Cancer Research|March 23, 2005
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinomaLars A Ormandy, Tina Hillemann, Heiner Wedemeyer, et al.
Gut|May 28, 2013
Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10Tobias Eggert, Katherine A McGlynn, Austin Duffy, et al.
Pageof 23